The use of emergency apheresis in the management of plasma cell disorders.

[1]  P. Ostojic,et al.  Managing refractory cryoglobulinemic vasculitis: challenges and solutions , 2017, Journal of inflammation research.

[2]  A. Santoro,et al.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology , 2016, Journal of Nephrology.

[3]  R. Rison,et al.  Paraproteinemic neuropathy: a practical review , 2016, BMC Neurology.

[4]  J. Miguel,et al.  Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study , 2015 .

[5]  S. Treon.  How I treat Waldenström macroglobulinemia. , 2009, Blood.

[6]  Xinxin Jiang,et al.  Double‐Filtration Plasmapheresis for Treatment of Acute Renal Failure in a Multiple Myeloma Patient , 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[7]  M. Stone,et al.  Role of plasmapheresis in Waldenström's macroglobulinemia. , 2013, Clinical lymphoma, myeloma & leukemia.

[8]  J. Winters.  Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. , 2012, Hematology. American Society of Hematology. Education Program.

[9]  P. Cockwell,et al.  The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney. , 2012, Advances in chronic kidney disease.

[10]  M. Misra,et al.  Role of plasmapheresis in the management of myeloma kidney: A systematic review , 2010, Hemodialysis international. International Symposium on Home Hemodialysis.

[11]  M. Stone.  Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. , 2009, Clinical lymphoma & myeloma.

[12]  S. Treon,et al.  Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. , 2008, Investigative ophthalmology & visual science.

[13]  D. Macdonald,et al.  Management of paraproteinaemia , 2007, Postgraduate Medical Journal.

[14]  S. Treon,et al.  Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. , 2006, Archives of ophthalmology.

[15]  B. Mcleod.  Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. , 2006, Best practice & research. Clinical haematology.

[16]  S. Singhal,et al.  Hyperviscosity syndrome in plasma cell dyscrasias. , 2003, Seminars in thrombosis and hemostasis.

[17]  A. Kaplan.  Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[18]  A. Kaplan.  Therapeutic apheresis for renal disorders. , 1999, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[19]  L. Wood,et al.  The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels , 1986, Journal of clinical apheresis.

[20]  J. Crawford,et al.  Evaluation of hyperviscosity in monoclonal gammopathies. , 1985, The American journal of medicine.

[21]  J. Stoltz.  Hemorheology: pathophysiological significance. , 1985, Acta medica portuguesa.

[22]  J. Beck,et al.  Hyperviscosity syndrome in paraproteinemia , 1982, Transfusion.

[23]  S. Urbaniak,et al.  Coagulation Abnormalities following Intensive Plasma Exchange on the Cell Separator , 1981, British journal of haematology.

[24]  R. Sassetti,et al.  Plasmapheresis with return of cryoglobulin-depleted autologous plasma (cryoglobulinpheresis) in cryoglobulinemia. , 1980, Blood.